RAC1 is a small, Ras-related GTPase that was recently reported to harbor a recurrent UV-induced signature mutation in melanoma, resulting in substitution of P29 to serine (RAC1 P29S ), ranking this the third most frequently occurring gain-of-function mutation in melanoma. Although the Ras family GTPases are mutated in about 30% of all cancers, mutations in the Rho family GTPases have rarely been observed. In this study, we demonstrate that unlike oncogenic Ras proteins, which are primarily activated by mutations that eliminate GTPase activity, the activated melanoma RAC1 P29S protein maintains intrinsic GTP hydrolysis and is spontaneously activated by substantially increased inherent GDP/GTP nucleotide exchange. Determination and comparison of crystal structures for activated RAC1 GTPases suggest that RAC1
RAC1 is a small, Ras-related GTPase that was recently reported to harbor a recurrent UV-induced signature mutation in melanoma, resulting in substitution of P29 to serine (RAC1 P29S ), ranking this the third most frequently occurring gain-of-function mutation in melanoma. Although the Ras family GTPases are mutated in about 30% of all cancers, mutations in the Rho family GTPases have rarely been observed. In this study, we demonstrate that unlike oncogenic Ras proteins, which are primarily activated by mutations that eliminate GTPase activity, the activated melanoma RAC1 P29S protein maintains intrinsic GTP hydrolysis and is spontaneously activated by substantially increased inherent GDP/GTP nucleotide exchange. Determination and comparison of crystal structures for activated RAC1 GTPases suggest that RAC1
F28L
-a known spontaneously activated RAC1 mutant-and RAC1
P29S are self-activated in distinct fashions. Moreover, the mechanism of RAC1 P29S and RAC1 F28L activation differs from the common oncogenic mutations found in Ras-like GTPases that abrogate GTP hydrolysis. The melanoma RAC1 P29S gain-of-function point mutation therefore represents a previously undescribed class of cancer-related GTPase activity.
cancer | cell signaling | x-ray crystallography | cytoskeleton | GEF-independent GTPase exchange R AC1, the Ras-related small GTPase belonging to the Rho family, functions as a binary molecular switch cycling between an inactive GDP-bound "OFF" state and an active GTP-bound "ON" state (1). Its activity is responsible for the regulation of diverse cellular behaviors including NADPH oxidase activation, formation of cortical actin-containing membrane ruffles and lamellipodia, and induction of gene expression programs (2) . Accordingly, these functions are tightly controlled through RAC1 lipidation, subcellular localization, protein expression levels, and Rho GDP-dissociation inhibitor (Rho GDI) interactions. In addition, as a GTPase, RAC1 is turned ON by guanine nucleotide exchange factors (GEFs) and is turned OFF by GTPase activating proteins (GAPs) that facilitate GDP/GTP nucleotide exchange and GTP hydrolysis, respectively. Once this regulation is compromised, RAC1 activity is implicated in various steps of oncogenesis including initiation, progression, invasion, and metastasis (3, 4) .
In contrast to Ras, RAC1 has rarely been identified as significantly mutated in cancer. Instead, overexpression of RAC1 has been reported in colorectal, pancreatic, breast, and testicular cancers and in various leukemias (5) (6) (7) . Additionally, a self-activating splice variant of RAC1, RAC1b, was shown to be overexpressed in breast cancer and lung cancer and is thought to mediate the epithelial-mesenchymal transition in lung epithelial cells (8) (9) (10) . Furthermore, aberrant activation of upstream regulators of RAC1, particularly in the DBL family of GEFs specific for RAC1 (e.g., TIAM1, PREX1, and ECT2), have been implicated in various cancers (11) . Although increased GDP→GTP nucleotide exchange in RAC1 (dependent or independent of GEFs) is important for mediating oncogenic effects, it is interesting that mutations or other aberrations in RAC1 GAPs are not commonly cancer-associated (3, 11) .
Recently, a recurrent somatic missense mutation at codon 29 of RAC1 that results in substitution of a proline to a serine residue (RAC1
P29S
) was discovered in up to 9% of sun-exposed melanomas. This discovery makes RAC1 the third most commonly mutated protooncogene in melanoma after BRAF and NRAS (12) (13) (14) . Additionally, RAC1
P29S is the most common cancer-associated recurrent missense mutation in a Rho family GTPase. The structural location of RAC1 codon 29 is distinct from the "hot spot" gain-of-function mutations found in Ras isoforms at codons 12 or 61 present in ∼30% of all cancers (Fig. 1) . Whereas the conserved residues at codons 12 and 61 are responsible for interacting with the β and γ phosphates of GTP, P29 is distal from the phosphates and is part of the Switch I region. Biochemical and cell-based assays demonstrated that RAC1 P29S is activated and has increased binding activity toward RAC1 effectors, and expression of mutant protein confers increased cell proliferation, altered cell migration, and stimulates membrane ruffling and MAPK signaling (12) . Crystallographic analysis of GTP analog-loaded RAC1 P29S also revealed an unusual GTP-bound Switch I conformation for a Rho family GTPase (12) . Understanding the gain-of-function mechanism is therefore important for dissecting the functional basis for signal activation and has implications for development of potential therapeutic intervention. Therefore, in the current study we have sought to determine the mechanism by which RAC1 P29S is activated. We demonstrate that unlike the common cancer-associated mutations in Ras, RAC1
P29S is a fast-cycling GTPase that occurs by a mechanism distinct from the previously described fast-cycling RAC1 mutant, RAC1
F28L
.
Results

RAC1
P29S Displays a Fast-Cycling Phenotype. To investigate the mechanism by which the P29S mutation activates RAC1, we first used an in vitro nucleotide exchange assay to monitor intrinsic activation of recombinant RAC1. It has previously been shown that wild-type RAC1 (RAC1 WT ) undergoes negligible nucleotide exchange while exposed to physiologic levels of Mg 2+ in vitro (16): This is because Mg 2+ is a cofactor for regulating RAC1 and other small GTPase nucleotide exchange kinetics, so Mg 2+ serves as a "gatekeeper" to RAC1 activation (17, 18) . Specifically, Mg 2+ coordination with RAC1 residues in the Switch I, Switch II, and P loops (T35, D57, and T17, respectively) serve to maintain a GDPbound inactive state (17) . Accordingly, chelation of Mg 2+ with EDTA can significantly increase GDP→GTP exchange in vitro. We therefore used a fluorescently labeled nonhydrolyzable GTP analog, N-methylanthraniloyl (MANT) Guanosine 5′-[γ-thio]triphosphate (mGTPγS), to increase fluorescence (excitation λ = 360 nm, emission λ = 440 nm) upon RAC1 binding to monitor nucleotide exchange for RAC1 preloaded with GDP (RAC1- Fig. 2A) . In contrast, RAC1 P29S undergoes inherent mGTPγS loading without addition of EDTA ( Fig. 2A) ). Residue F28 is adjacent to P29, is highly conserved in the Ras superfamily, and is known to stabilize the guanine base of GDP and GTP nucleotides (16, 19) . Substitution of F28 to leucine in RAC1 results in spontaneous activation and transforms cells while maintaining GTP hydrolysis, results that suggest a "fast-cycling" phenotype (20) . In other Rho family GTPases, the F28L mutation was also found to be fast-cycling, to activate Rho family-mediated signaling pathways, and to induce in vitro cell transformation (16, 20 , P < 0.001). RAC1 F28L displayed significantly faster exchange than RAC1 P29S on addition of EDTA (P < 0.01) (Fig. 2B and Fig. S1 ).
The p21-activated kinase (PAK) group of serine-threonine kinases are well-established effectors of RAC1 and other Rho family GTPases (21) . We therefore tested whether an in vitro PAK1 pull-down assay could provide further evidence for RAC1 P29S as a self-activated GTPase. RAC1
WT displayed association with PAK1 when loaded with nonhydrolyzable GTP analog, Guanosine 5′-[γ-thio]triphosphate (GTPγS), but not when preloaded with GDP ( Fig. 2C and Fig. S2B ). Furthermore, on addition of GTPγS, both RAC1 P29S and RAC1 F28L show appreciably increased PAK1 binding compared with that of RAC1 WT (Fig. 2C ). As expected, PAK1 did not associate with RAC1
T17N
, a known dominant-negative mutation that abrogates nucleotide binding (Fig. 2C) . The addition of EDTA to facilitate GTPγS loading in RAC1
WT is comparable to that observed for RAC1 P29S and RAC1 F28L in the absence of EDTA. This orthogonal method correlates well with the fluorescence exchange assay ( Fig. 2 A and B) and confirms RAC1 P29S as a fast-cycling mutant.
RAC1
P29S Maintains Its Ability to Hydrolyze GTP. In the Ras superfamily, most of the common hot-spot oncogenic mutations affect the enzyme's ability to hydrolyze GTP resulting in a constitutively GTP-bound activated GTPase (22) . We therefore investigated the intrinsic ability of RAC1 P29S to hydrolyze GTP. An α-carbonradiolabeled GTP ([α- . RAC1
P29S displayed an increased GTPase activity in all reaction conditions compared with that of RAC1
WT but similar [α-32 P]GDP production as that of RAC1 F28L (Fig. 3A) . The known hydrolysis-inactive RAC1 Q61L mutant used as a control showed no [α-32 P]GDP production. Titration of EDTA into these reactions allowed us to determine that in the presence of 20 mM EDTA, RAC1
WT yields approximately similar [α-
32 P]GDP production as that of RAC1 P29S or of RAC1 F28L at 10 mM EDTA (Fig. 3A) . This assay suggested that the increase in [α- 32 P]GDP production of these mutants is due to increased inherent nucleotide exchange rates resulting in an increased enzyme turnover rate. Second, we used a hydrolysis assay (23) to determine if the first-order hydrolysis rate of GTP-bound RAC1 was affected by the mutations. RAC1 was loaded with [α- WT and the two fast-cycling mutants displayed similar intrinsic GTP hydrolysis rates, and RAC1 Q61L was unable to hydrolyze GTP ( Fig.  3B and Fig. S3) . Our data therefore demonstrate that like RAC1 F28L , RAC1 P29S is a fast cycler, and it maintains similar intrinsic GTP hydrolysis as that of RAC1
WT . To investigate the fast-cycling behavior further, we conducted structural studies.
Structural Basis for a Fast-Cycling RAC1 GTPase. In light of our biochemical analyses, we examined the possibility of whether RAC1 P29S and RAC1
F28L would have similar structural bases for self-activation. We previously determined the structures of RAC1 P29S and RAC1
WT in the presence of nonhydrolyzable GTP analogs and observed a significant difference in the conformation of the Switch I loop resulting in RAC1 P29S adopting a Ras-like Switch I conformation (12). To investigate whether there was a difference between WT (PDB ID code 3TH5) (12) with key regions indicated shown in cartoon format. Red spheres identify the residues described in the paper. The exploded view shows the Switch regions with side chains in cylinder format. Structural figures generated using CCP4MG (15) . WT and RAC1 P29S . RAC1 P29S is a self-activating mutant as indicated by inherent self-association of mGTPγS without the addition of EDTA (Left). EDTA (20 mM) is added to facilitate RAC1
WT nucleotide exchange (Right). In both experimental conditions, RAC1
WT is significantly slower than RAC1 P29S (P < 0.05 GTP-loaded RAC1 F28L and RAC1
P29S
, we determined the 2.8 Å crystal structure of RAC1 F28L bound to nonhydrolyzable GTP analog GTPγS (Table 1, Fig. 4, and Fig. S4 ). While the overall structure of RAC1 F28L is similar to that of RAC1 P29S (rmsd of 0.5 Å over 174 Cα residues), we observe that in contrast to RAC1 P29S , RAC1
F28L adopts a wild-type-like conformation in its Switch I loop, with increased flexibility (based on temperature factor and electron density analysis) similar to that of solution structures of the CDC42 F28L mutant (24, 25) . The F28L mutation in RAC1 also results in a loss of interaction between codon 28 and the nucleoside, suggesting that for RAC1 F28L , fast cycling results from reduced affinity for nucleotide. In contrast, for both RAC1
WT and RAC1
, F28 contacts the guanosine moiety. To confirm the Switch I conformation adopted by catalytically inactive mutants of RAC1, we determined the 2.0 Å crystal structure of RAC1 Q61L in complex with nonhydrolyzable GTP analog 5′-Guanylyl imidodiphosphate (GMP-PNP) ( Table 1). RAC1 Q61L also exhibited a wild-type-like conformation for the Switch I loop (Fig. 4) , but like RAC1
WT and RAC1 P29S also displayed close interactions between F28 and the nucleoside. These structural and biochemical data suggest that RAC1 F28L and RAC1 P29S are self-activated by different mechanisms, with RAC1 F28L self-activation driven by a loss in interaction between the guanine ring and F28, and RAC1 P29S is possibly driven by another mechanism, perhaps destabilization of the GDP-loaded inactive state.
Cell Morphological Effects of Distinct Classes of RAC1 Activated
Mutants. One of the cellular hallmarks of an activated RAC1 GTPase is the appearance of membrane ruffles (20, 26) . We previously demonstrated that transfected GFP-RAC1 P29S in cells accumulates in membrane ruffles, which contrasted with a more diffuse cytoplasmic localization for GFP-RAC1 WT suggesting that RAC1 P29S is activated in vivo. As both RAC1 F28L and RAC1
Q61L
are also activated in vivo, we compared their ability to induce membrane ruffling in live COS-7 cells using N-terminal GFP fusion proteins (20, 26) . A ruffling index to score the extent of GFP-RAC1 accumulation at membrane ruffles was used, and an average ruffling index was calculated for each GFP-RAC1 cell population (n > 20). RAC1
WT -expressing cells displayed an average membraneruffling index of 0.54 ± 0.16 (n = 22), whereas GFP-RAC1
P29S
expressing cells displayed a significantly increased average ruffling index of 1.54 ± 0.14 (n = 22, P < 0.0001). Both RAC1 F28L -expressing cells and RAC1
Q61L
-expressing cells had similar ruffling indexes (1.54 ± 0.12, n = 28, and 1.64 ± 0.14, n = 22, respectively) as that of RAC1
P29S
-expressing cells and were also significantly enriched for membrane ruffles compared with RAC1 WT -expressing cells (P < 0.0001) suggesting that each class of RAC1 mutation (fast cycling vs. hydrolysis dead) can induce an activated RAC1 cellular phenotype (Fig. 5 A and B) . Notably, GFP-RAC1 expressing cells, ∼45% contained more than one nucleus. Multinucleation has previously been shown for GTPase-defective RAC1 mutants (codon 12 or 61 mutants) and is thought to be because RAC1 activity is a negative regulator of the actomyosin contractile ring construction and can inhibit cytokinesis (27) and RAC1 accumulates in the nucleus during the G2 phase of the cell cycle (28) . Finally, we compared the morphological effects of the fast-cycling RAC1 mutants in stable NIH 3T3 fibroblast cell lines. We observed that NIH 3T3 cells expressing the fast-cycling mutants as N-terminal Flag-tagged proteins displayed increased membrane ruffling compared with that of RAC1 WT (Fig. 5B) . We also assayed F-actin stress fibers in conjunction with RAC1 localization and found that both RAC1 P29S and RAC1 F28L maintained similar F-actin cellular structures (Fig. 5B) . These assays confirm a similar phenotype for RAC1 P29S as that of known RAC1 activating mutations.
Discussion
In this study, we investigate the properties of the mutated Rho family GTPase, RAC1 P29S . Discovery of the P29S mutation has placed RAC1 as a commonly mutated gene in melanoma and has highlighted the potential of RAC1 effector pathways as potential therapeutic targets (12, 13) . Strikingly, this is the most commonly found recurrent missense mutation to be discovered in a Rho family GTPase. Additionally, the location of P29S is distinct from the commonly found oncogenic mutations in the Ras oncogenes. We therefore studied the biochemical and structural properties of RAC1 P29S in comparison with other well-studied RAC1 mutations. We found that RAC1 P29S is a spontaneously activating GTPase with significantly increased inherent GDP→GTP nucleotide exchange compared with that of RAC1 WT . This behavior is similar to the previously described RAC1 F28L fast-cycling mutant, although notably we found that RAC1 F28L displays faster mGTPγS association kinetics than RAC1
P29S
. We corroborated RAC1 P29S as a fast-cycling GTPase by an orthogonal nucleotide exchange assay that tested the ability of GDP-loaded RAC1 to pull-down with the GTPase-binding domain of PAK1. Both assays suggest that RAC1 P29S and RAC1 F28L are able to exchange GDP for GTP (or GTP analog) without chelation of Mg
2+
. Additionally, we found that RAC1 P29S maintains its inherent ability to hydrolyze GTP. This contrasts with oncogenic forms of Ras that lose their enzymatic activity. We do not know of another frequently recurrent cancer-associated GTPase mutation where spontaneous activation is observed, although P29L in RAC2 has been infrequently observed in melanoma and breast cancer (29, 30) , potentially suggesting that fast-cycling mutations in other Rho family GTPases could also be associated with cancer. Notably, cellular imaging of live COS-7 cells suggests that fast-cycling RAC1 mutants (F28L, P29S) behave in a distinct manner in vivo compared with GTPasedefective RAC1 mutants (Q61L), whereas RAC1 
and RAC1
Q61L all displayed similarly significant induction of membrane ruffling compared with RAC1 WT . For RAC1 Q61L , there was a marked increase in cells exhibiting multinucleation (Fig. 5A ). This could suggest that the GDP/GTP "flux" of Rho family GTPases is important for oncogenesis.
To investigate the mechanism of RAC1 P29S activation further, we determined the crystal structures of RAC1 F28L and RAC1 Q61L and compared these to the structures of RAC1
WT and RAC1 P29S that we have recently described (12) . Although the overall architectures were very similar, the conformation of the Switch I loops of RAC1 P29S and RAC1 F28L were divergent from each other, with RAC1
P29S showing a Ras-like Switch I conformation and RAC1 F28L displaying increased flexibility. For RAC1
F28L
, this is probably due to the loss of the phenylalanine benzyl group and consequent reduced stabilizing interactions with nucleotide. On comparison of the GTP analog-loaded crystal structures of RAC1 P29S and RAC1
, it seems clear that the basis for RAC1 P29S fast-cycling is not due to reduced interaction with GTP, rather the GDP-loaded state may be destabilized (13) . Although destabilization by P29S mutation may preclude cocrystallization of RAC1 P29S with GDP, this could be a tractable NMR target.
Mutation of codon 29 could also impact the interactions of RAC1 with GTPase regulatory proteins, Rho GDIs, GAPs, and GEFs, and with downstream effectors. The current studies do not provide a clear understanding of how the interactions of RAC1 with regulators and effectors is affected by P29S or what is the impact of the P29S substitution on binding affinities for GTP or GDP, but our results allow some predictions. Specifically, for GDI interactions, structural analyses of Rho GTPases in complex with Rho GDIs suggest that P29 is distal from the bound GDI by over 12Å, therefore unlikely directly to impact the binding interface. However, these interactions are dependent on the GTP-binding state of the GTPase (31), implying that for the fast-cycling RAC1
P29S
, there could be altered interactions with GDI. For GAP-mediated hydrolysis, although P29 is distal from the site of hydrolysis, it has previously been shown that allosteric effects can impact GAP- mediated hydrolysis for Ras and elongation factor Tu (EF-Tu) (32, 33) , therefore there is the possibility that allosteric effects could play a role for RAC1
. For GEF-mediated nucleotide exchange, although we show that RAC1 P29S spontaneously exchanges in the absence of nucleotide exchange factor, the mutation also has the potential to alter response to GEFs. For downstream effectors, there is also the possibility that certain downstream effectors may bind with greater avidity to the RAC1 P29S compared with the wildtype protein, potentially affecting discrete signaling pathways. Finally, the impact of P29S mutation on nucleotide-binding affinity could also alter RAC1 signaling. We note that the Rho subfamily of GTPases, which contain an extremely well conserved proline at codon 29, bind GTP in the submicromolar range (18); however, the Ras subfamily of GTPases, which do not have a proline at codon 29, bind GTP in the subnanomolar range (34) . We previously showed that RAC1
P29S adopts a Ras-like conformation when complexed to a GTP analog (12) (Fig. 4) , potentially suggesting altered RAC1 P29S affinity for GTP, additional to the driving fast-cycling behavior described here.
The Ras GTPases suffer the most frequent gain-of-function mutations of all oncogenes in cancer (∼30%) mainly at codons 12 and 61 ( Fig. 1) (35) . These oncogenic Ras mutations abrogate GTP hydrolysis (Fig. 3) (36) and mediate their oncogenic potential through the inability of Ras to hydrolyze GTP to GDP, therefore locking the GTPase in an activated state with consequent effector activation (36) . Strikingly, until now there have been very rare recurrent cancer-associated mutations discovered in Rho family GTPases, and although mutation of F28 in CDC42 can transform cells (16, 20) , it has not yet been found in patients. Furthermore, P29S in RAC1 is the first example of a fast-cycling cancer-associated GTPase mutation that is frequently recurrent in melanoma. Therefore, RAC1
P29S represents a previously undescribed class of cancer-associated mutation; a recurrent Rho family spontaneously activated GTPase.
Materials and Methods
In Vitro RAC1 Fluorescent GTPγS Exchange Assay. Purified RAC1 recombinant protein (250 nM) preloaded with GDP. RAC1-GDP was added into loading buffer (20 mM Tris·HCl, pH 7.5/50 mM NaCl/10 mM MgCl 2 ) containing 500 nM mGTPγS with and without 20 mM EDTA (concentration as indicated in Fig. S2 A and B) with constant stirring at a total volume of 2 mL. The mGTPγS fluorescence was monitored in real time (excitation λ = 360 nm, emission λ = 440 nm) using a Photon Technology International SC-500 spectrometer. Rate constants were calculated using GraphPad's single-phase exponential
]) to fit the association of mGTPγS proteins as measured through relative fluorescence unit (RFU) increase. Loading controls for these experiments are shown in Fig. S2 .
In Vitro RAC1 GTP Hydrolysis Assay. Two in vitro RAC1 GTP hydrolysis assays using a radiolabeled α-carbon GTP ([α- 32 , and enzyme turnover was inhibited with excess GTPγS (20 μM final concentration). For both assays at indicated time points, 1 μL of the reaction mixture was stopped in 4 μL of a stop mixture containing 2 mM EDTA and 0.5% SDS, and 1 μL of this reaction stop mixture was spotted on the TLC plate. After the liquid-phase run, the plates were dried and allowed to develop on a Phosphor screen for at least 16 h and imaged. Loading controls for these assays are included in Fig. S2C .
In Vitro RAC1 Activation Assay. Purified recombinant RAC1 proteins (30 μM) that had been previously loaded with GDP were either incubated with 500 μM GTPγS with or without 10 mM EDTA to facilitate nucleotide exchange or left bound to GDP at room temperature for 1 h, and exchange was quenched by addition of 10 mM MgCl 2 (final volume). Next, 5 μg RAC1 nucleotide complexes was incubated with 5 μg Glutathione Sepharosebound GST-PAK1-GBD domain (PAK1 amino acids 67-150) and incubated while rotating at 4°C for 60 min in 500 μL cold pull-down buffer [25 mM Tris·HCl, pH 8.0/40 mM NaCl/30 mM MgCl 2 /1 mM DTT/1% (vol/vol) Nonidet P-40]. After incubation, beads were washed three times with ice-cold pulldown buffer. Pull-down efficiency was then assayed via immunoblotting. Loading controls of this assay are included in Fig. S2B .
Generation of Stable NIH 3T3 Cell Lines. A modified 3× FLAG lacking any enterokinase cleavage site (DYKDHDGDYKDHDIDYKDHDG) was used to N-tag RAC1. NIH 3T3 cells stably expressing these 3×-FLAG-RAC1 constructs were created by transfecting 7.5 μg 3×-FLAG-RAC1 pSMPUW-Hygro (Cell Biolabs) plasmids using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen) and selected with 200 μg/mL hygromycin for 2 wk. All RAC1 mutants were generated according to the QuikChange site-directed mutagenesis method following the manufacturer's protocol (Agilent Technologies).
Fluorescence Microscopy. COS-7 cells were transiently transfected with 1. , and 3×-Flag-RAC1 F28L were immunostained with anti-FLAG and probed with Alexa-Fluor 488 to visualize RAC1 expression, and subcellular localization and integrity of F-actin-containing stress-fibers was visualized through staining with rhodamine phalloidin. In both RAC1 P29S -and RAC1
F28L
-expressing cells, membrane ruffling was observed as in COS-7 cells; ruffling is indicated with white arrows. examined (n > 20 for each construct), a membrane-ruffling index was assigned where 0 = no membrane ruffling, 1 = <25% membrane ruffling present on the cell surface in one defined area, and 2 = two or more discrete areas displaying membrane ruffling present. From the sum of the membrane-ruffling index, an average ruffling index was calculated for each construct. Multinucleated cells were counted manually. . For in vitro experiments,  recombinant RAC1  WT , RAC1   P29S   , RAC1   F28L , and RAC1 Q61L were expressed as N-terminal hexahistidine (6xHis)-tag in BL21(DE3) cells and induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 12 h at 16°C. The fusion protein was affinity purified, and the protein was then loaded on a Superdex 200 HiLoad 26/60 (GE Healthcare) column in a buffer of 20 mM Tris·HCl (pH 8.0), 150 mM NaCl, and 1 mM DTT.
RAC1 Purification for in Vitro Experiments
RAC1
F28L and RAC1 Q61L Expression and Purification for Crystallization. RAC1
F28L
and RAC1 Q61L spanning residues 2-177 were subcloned into a modified pET-28 vector with a 6xHis-tag and cleaved by Tobacco Etch Virus (TEV) protease, which produces N-terminally 6xHis-tagged RAC1. Recombinant RAC1 F28L and RAC1 Q61L were expressed as N-terminal 6xHis-tagged proteins in BL21-CodonPlus(DE3)RILP cells and induced with 1 mM IPTG for 24 h at 18°C. Briefly, the recombinant proteins were affinity purified by HisTrap chelating column (GE Healthcare) and then loaded on a Superdex 75 10/300 GL (GE Healthcare) column in a buffer of 20 mM Tris·HCl (pH 8.0), 150 mM NaCl, and 1 mM DTT. For crystallization, the purified proteins were concentrated to 4 mg/mL in a buffer of 20 mM Tris, 150 mM NaCl, 1 mM DTT, 5 mM MgCl 2 , with 1 mM GTPγS for RAC1 F28L or 1 mM GMP-PNP for RAC1 Q61L .
RAC1
F28L and RAC1 Q61L Crystallization. Crystals of RAC1 F28L were grown by hanging drop methodology in a 1:1 volume ratio of purified RAC1 F28L and reservoir solution containing 0.1 M Hepes (pH 7.5), 16-18% (vol/vol) PEG 4000, and 8% (vol/vol) isopropanol at room temperature. Crystals were equilibrated in a cryoprotectant buffer containing reservoir buffer plus 25% (vol/vol) glycerol and were flash frozen in a nitrogen stream at 100 K. X-ray data from a single crystal were collected to 2.8 Å resolution using Beamline 24-ID-C at the Advanced Photon Source (APS). Crystals of RAC1 Q61L were grown by hanging drop methodology in a 1:1 volume ratio of purified RAC1 Q61L and reservoir solution containing 0.1 M Hepes (pH 7.5), 16-18% (vol/vol) PEG 4000, and 6% (vol/vol) isopropanol at room temperature. Crystals were equilibrated in a cryoprotectant buffer containing reservoir buffer plus 25% (vol/vol) glycerol and were flash frozen in a nitrogen stream at 100 K. X-ray data from a single crystal were collected to 2.0 Å resolution using Beamline X29 at the National Synchrotron Light Source (NSLS).
Structure Determination and Refinement. RAC1 F28L and RAC1 Q61L data were processed using the HKL2000 package (38) , and initial phases were calculated by molecular replacement using the program Phaser (39) (Table 1) . One hundred percent of residues fall within favored or allowed regions of the Ramachandran plot. Good electron density is observed throughout the structure, including GTPγS and GMP-PNP, however residues G30 (chain A) and E31 and G48 (chain B) in RAC1 Q61L are not visible in the electron density.
Structures have been deposited in the PDB (PDB ID codes 4GZL and 4GZM).
